Suven Life Sciences to Present Seven CNS Pipeline Posters at Neuroscience 2026
Suven Life Sciences Ltd · Press Release · 12 Nov 2026, 5:14 pm
Suven Life Sciences to Present Seven CNS Pipeline Posters at Neuroscience 2026 Suven Life Sciences announced it will present seven scientific posters showcasing its CNS drug discovery and development pipeline at Neuroscience 2026 in Washington, DC, scheduled for 14th–18th Nov'26. Presentations highlight key clinical and preclinical assets targeting Alzheimer’s disease, narcolepsy, depression, and schizophrenia. Key pipeline updates include Phase-3 candidates Masupirdine (SUVN-502) and Samelisant (SUVN-G3031), Phase-2b data for Ropanicant (SUVN-911) with Phase-3 planning underway, and First-in-Human Phase-1 results for Tenaclidine (SUVN-I6107). Suven holds full intellectual property rights globally across its five clinical-stage assets and seven research projects.
Original exchange filing (PDF)
More announcements from Suven Life Sciences Ltd
- Please find enclosed the Revised News Release of our company · 16 Nov 2026
- Please find enclosed the News Release of our Company · 16 Nov 2026
- Monitoring Agency Report for the quarter ended 30th September, 2026 · 06 Nov 2026
- Un-audited financial results for the quarter and half year ended 30th September 2026 · 05 Nov 2026
- Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026 · 05 Nov 2026
- Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 05 Nov 2026
